2009
DOI: 10.3748/wjg.15.441
|View full text |Cite
|
Sign up to set email alerts
|

Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor γ involves angiogenesis inhibition

Abstract: AIM:To study the possible actions and mechanisms of peroxisome proliferator-activated receptor γ (PPARγ), a ligand-activated transcription factor, in pancreatic carcinogenesis, especially in angiogenesis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
29
0

Year Published

2009
2009
2018
2018

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 45 publications
(30 citation statements)
references
References 18 publications
1
29
0
Order By: Relevance
“…In this context, antimetastatic but not anti-proliferative effects were also reported after treatment of pancreas cancer with a synthetic PPAR-ligand (T0070907), known to be a specific PPARantagonist (Nakajima et al, 2008). In contrast, PPAR-agonists were shown to inhibit the growth of pancreas tumours via downregulation of VEGF and thus inhibition of tumour angiogenesis (Dong et al, 2009). This is in line with previous observations suggesting an involvement of PPAR-signalling in the angiogenesis process (Panigrahy et al 2002).…”
Section: Influence Of Ppar On Pancreas Metastasissupporting
confidence: 79%
“…In this context, antimetastatic but not anti-proliferative effects were also reported after treatment of pancreas cancer with a synthetic PPAR-ligand (T0070907), known to be a specific PPARantagonist (Nakajima et al, 2008). In contrast, PPAR-agonists were shown to inhibit the growth of pancreas tumours via downregulation of VEGF and thus inhibition of tumour angiogenesis (Dong et al, 2009). This is in line with previous observations suggesting an involvement of PPAR-signalling in the angiogenesis process (Panigrahy et al 2002).…”
Section: Influence Of Ppar On Pancreas Metastasissupporting
confidence: 79%
“…PPAR-c is a nuclear receptor serving as a transcription factor to control cell differentiation, apoptosis and glucose metabolism (Kliewer and Wilson 1998). Ligands for PPAR-c such as anti-diabetic drugs of the thiazolidinedione (TDD) class pioglitazone, troglitazone and rosiglitazone (Cho and Momose 2008;Krentz et al 2008) exert anti-inflammatory effects and reduce PC growth in experimental models (Nakajima et al 2008;Dong et al 2009). The antiinflammatory effects associate with suppression of COX-2 and NF-jB activities, evidencing complex intracellular pathways and their suppression of tumor growth partially occurs via reducing VEGF (Dong et al 2009).…”
Section: Ppar-c Ligands: General and Pancreas Cancer-specific Anti-tumentioning
confidence: 99%
“…Ligands for PPAR-c such as anti-diabetic drugs of the thiazolidinedione (TDD) class pioglitazone, troglitazone and rosiglitazone (Cho and Momose 2008;Krentz et al 2008) exert anti-inflammatory effects and reduce PC growth in experimental models (Nakajima et al 2008;Dong et al 2009). The antiinflammatory effects associate with suppression of COX-2 and NF-jB activities, evidencing complex intracellular pathways and their suppression of tumor growth partially occurs via reducing VEGF (Dong et al 2009). The expression of PPAR-c in human PC and the effects of its ligands on cell growth were studied (Sasaki et al 2001).…”
Section: Ppar-c Ligands: General and Pancreas Cancer-specific Anti-tumentioning
confidence: 99%
“…Thus, the level of proliferating cell nuclear antigen (PCNA), an established index for proliferation cells, was firstly assessed to determine cell proliferation in PANC-1 cells [14] . Western blot analysis clearly shows that PCNA protein expression undergoes a down-regulation change in a time-dependent manner after exposure to ASA (Figure 2A).…”
Section: Asa Decreases Proliferation Instead Of Inducing Apoptosis Ormentioning
confidence: 99%